An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as
the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination